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Abstract
Background: The recreational use of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy)
among adolescents and young adults has become increasingly prevalent in recent years. While
evidence suggests that the long-term consequences of MDMA use include neurodegeneration to
serotonergic and, possibly, dopaminergic pathways, little is known about susceptibility, such as
behavioral sensitization, to MDMA.
Methods: The objectives of this study were to examine the dose-response characteristics of acute
and chronic MDMA administration in rats and to determine whether MDMA elicits behavioral
sensitization and whether it cross-sensitizes with amphetamine and methylphenidate. Adult male
Sprague-Dawley rats were randomly divided into three MDMA dosage groups (2.5 mg/kg, 5.0 mg/
kg, and 10.0 mg/kg) and a saline control group (N = 9/group). All three MDMA groups were treated
for six consecutive days, followed by a 5-day washout, and subsequently re-challenged with their
respective doses of MDMA (day 13). Rats were then given an additional 25-day washout period,
and re-challenged (day 38) with similar MDMA doses as before followed by either 0.6 mg/kg
amphetamine or 2.5 mg/kg methylphenidate on the next day (day 39). Open-field locomotor
activity was recorded using a computerized automated activity monitoring system.
Results: Acute injection of 2.5 mg/kg MDMA showed no significant difference in locomotor
activity from rats given saline (control group), while animals receiving acute 5.0 mg/kg or 10.0 mg/
kg MDMA showed significant increases in locomotor activity. Rats treated chronically with 5.0 mg/
kg and 10.0 mg/kg MDMA doses exhibited an augmented response, i.e., behavioral sensitization, on
experimental day 13 in at least one locomotor index. On experimental day 38, all three MDMA
groups demonstrated sensitization to MDMA in at least one locomotor index. Amphetamine and
methylphenidate administration to MDMA-sensitized animals did not elicit any significant change in
locomotor activity compared to control animals.
Conclusion: MDMA sensitized to its own locomotor activating effects but did not elicit any cross-
sensitization with amphetamine or methylphenidate.
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The recreational use of 3,4-methylenedioxymethamphet-
amine (MDMA, ecstasy) has become increasingly preva-
lent in recent years, with the highest incidence of use
reported in adolescent and young-adult populations
[1,2]. An estimated 6.4 million individuals have used
MDMA, and its use has risen over the past decade [3]. This
high rate of use, especially in younger human popula-
tions, is alarming since many animal studies have corre-
lated MDMA use with the onset of lasting cognitive and
behavioral deficits, including impairments in spatial
memory and learning, increased anxiety-like behavior,
and a weakened ability of the nervous system to react to
stressful stimuli [4-12], while the addictive potential of
MDMA, such as behavioral sensitization, remains poorly
understood.
MDMA is a ring-substituted amphetamine derivative with
a structural resemblance to the hallucinogen mescaline
[13]. Physiological effects of MDMA use include hyperac-
tivity [14-16], hyperthermia [17-20], and hyponatremia
[19,21]. Pharmacologically, MDMA potently causes an
acute rise in extracellular serotonin (5-HT), which is often
behaviorally manifested as "5-HT syndrome" in rats
[8,9,14], characterized by low body posture, forepaw
treading, and head-weaving. MDMA also causes an acute
rise in extracellular dopamine (DA) levels [22,23]. The
chronic administration of MDMA has been well-charac-
terized for causing long-term persistent depletions in
brain 5-HT levels, most likely due to the neurotoxic action
of MDMA to 5-HT-releasing neurons [7,24]. In light of the
increased incidence of MDMA use along with data sug-
gesting neurotoxicity and long-term cognitive and behav-
ioral deficits linked to its use, a good understanding of its
potential to elicit dependence and abuse is paramount.
Behavioral sensitization is one of the experimental mark-
ers to indicate the potential of a drug to produce depend-
ence [25-27]. Behavioral sensitization is characterized by
a progressively augmented response following repetitive
administration of a drug. It is an accepted experimental
model to verify for dependency on a drug [25-27].
Although the behavioral sensitization to psychostimu-
lants such as cocaine [27], amphetamine [26,28,29], and
methylphenidate [30-32] has been well characterized, the
effects of repeated MDMA administration on locomotor
activity are contradictory, with some studies suggesting
that MDMA elicits behavioral sensitization [18,27,33],
and some showing that MDMA causes tolerance [8,34] or
neither [16].
Furthermore, behavioral cross-sensitization, which is the
augmentation that occurs when pretreatment with one
stimulant leads to greater sensitivity to another stimulant,
has been established between psychostimulants, includ-
ing between cocaine and amphetamine [35], methylphe-
nidate and amphetamine [36], and methylphenidate and
cocaine [37]. Kalivas et al. [27], Itzhak et al. [38], and
Achat-Mendes et al. [39] reported that repeated MDMA
treatment prior to cocaine resulted in an elevated behav-
ioral response to cocaine. Pre-exposure to MDMA, there-
fore, may induce a cross-sensitized response to other
psychostimulants such as amphetamine and methylphe-
nidate.
The present study examined the acute and chronic dose-
response characteristics on locomotor activity in adult
male Sprague-Dawley rats following MDMA and subse-
quently further re-challenged with amphetamine or meth-
ylphenidate. This was done to determine whether MDMA
can elicit behavioral sensitization as well as to cross-sensi-
tize with other psychostimulants. A sensitized and/or
cross-sensitized response could prove invaluable in deter-
mining the potential of MDMA to elicit dependence/
addiction [40] and increased susceptibility to abuse of
other addictive psychostimulants [27,41].
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Controls
In general, saline injections slightly increased locomotor
activity during the first 10-minutes post-injection and
returned to baseline and remained stable during the entire
recording session. Figure 1 shows the activity following 2
consecutive saline injections (experimental days 1 and 2)
and demonstrates that activity measured on these two
days is similar. Therefore, any changes in locomotor activ-
ity recorded that deviate from saline group values
obtained on experimental day 2 following MDMA treat-
ment is recognized as an effect of the drug treatment. Pre-
vious time control experiments performed by this
laboratory on rats given daily saline injections for 42 days
have exhibited stable and similar baseline locomotor
activity over the course of experiments [42].
Dose-response effects of acute (single-injection) MDMA 
administration
The general effects of MDMA were dose-dependent
increases in locomotor activity across the indices meas-
ured. The lowest dose of MDMA (2.5 mg/kg on experi-
mental day 2), however, showed no effects on any of the
locomotor indices studied versus animals given saline.
Rats given 5.0 mg/kg MDMA on experimental day 2 (Fig.
1) showed trends of increases in HA, TD, VA and NOS, but
only the increases in the HA and NOS indices were signif-
icant (p < 0.05) compared to animals given 2.5 mg/kg or
saline. Animals injected with 10.0 mg/kg MDMA showed
a significant (p < 0.05) increase in all four locomotor indi-
ces (HA, TD, VA, and NOS) when compared to the saline
or to 2.5 mg/kg MDMA groups. Animals receiving 10.0
mg/kg MDMA also had significantly (p < 0.05) higher
activity than animals receiving 5.0 mg/kg across the HA,
TD, and NOS indices.
Dose-response effects of chronic (multiple-injection) 
MDMA administration
The total 2-h locomotor activity obtained on experimental
days 1, 2, 7, 13 and 38 for the four indices is summarized
in figure 2. Saline injections (Fig. 2) had no effect on loco-
motion and were similar for all the indices (HA, TD, VA,
and NOS) studied. The effect of 6 consecutive daily
MDMA exhibit similar locomotor activity, i.e. the initial
response to MDMA on experimental day 2 was similar to
experimental day 7. However, after 5 days of washout
(experimental day 13), animals treated with 2.5 mg/kg
(i.e., experimental day 13) MDMA showed a significant
increase in locomotor activity across all four locomotor
indices when compared with experimental day 2. This sig-
nificant increase in locomotion expresses behavioral sen-
sitization. These same animals, however, showed no
significant change in response to 2.5 mg/kg, i.p, MDMA
on experimental day 38; i.e., the repetitive treatment of
2.5 mg/kg MDMA elicited sensitization of a transient
nature (Fig. 2). Animals treated with 5.0 mg/kg MDMA
showed significant increases in locomotor activity on
experimental day 13 across the HA, TD, and NOS indices.
After 25 days of washout (on experimental day 38), ani-
mals re-challenged with 5.0 mg/kg exhibited sensitization
across the HA, VA and NOS indices. The locomotor sensi-
tization elicited by the 5.0 mg/kg dose thus persisted for a
longer period of time than that of the 2.5 mg/kg dose. In
animals injected with 10.0 mg/kg MDMA, the initial high
dose elicited a robust increase in locomotor activity, but
only the HA and VA indices exhibited sensitization on
experimental day 13 and again (25 days later) on experi-
mental day 38 (Figure 2).
The effects of chronic MDMA administration on animal
weight and rate of weight gain were not significant com-
pared to animals receiving saline (data not shown).
Temporal dose-response characteristics of MDMA on 
locomotor activity
Figures 3 and 4 summarize the temporal dose-response
characteristics of the HA and NOS indices, on experimen-
tal day 2, 7, 13 and 38, respectively. To determine any sig-
nificant change from baseline values due to drug action,
we designated (prior to the experiment) that after drug
treatment at least two consecutive 10-minute bins (i.e.,
significant changes over 20 minutes) with an activity
count significantly different (p < 0.05) from the corre-
sponding 10-minute bins were needed in order to charac-
terize the response to the drug as being significantly
different from baseline. Based on this criterion, animals
injected repeatedly with 2.5 mg/kg MDMA did not express
significant change (on experimental days 7, 13, and 38)
compared to experimental day 2 in HA (Fig. 3) or TD
(data not shown) but showed a significantly increased
response in the NOS index on experimental day 13 and
experimental day 38 (Fig. 4). Animals injected with 5.0
mg/kg MDMA showed a significant change in the HA and
NOS indices in response to MDMA on experimental days
13 and 38, respectively (Figs. 3 and 4). Animals injected
with repeated 10.0 mg/kg MDMA showed significant
changes in HA (compared to experimental day 2) only in
the HA index, seen on experimental days 7, 13, and 38
(Fig. 3). Sensitization was therefore observed and was per-
sistent.
Interaction between MDMA and amphetamine or 
methylphenidate
On experimental day 39, six out of nine animals were
treated with amphetamine while the remaining three were
treated with 2.5 mg/kg methylphenidate (see Table 1 for
experimental protocol). The locomotor activity in the
saline group resulting from single amphetamine or single
methylphenidate injection on experimental day 38 was
used as control to compare with the locomotor activityPage 3 of 12
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summarizes the experiments measuring the chronic dose-response to MDMA (2.5, 5.0, and 10.0 mg/kg, i.p.) for the HA, TD, VA, and NOS locomotor indicesFigure 2
summarizes the experiments measuring the chronic dose-response to MDMA (2.5, 5.0, and 10.0 mg/kg, i.p.) for the HA, TD, 
VA, and NOS locomotor indices. The values are presented as the mean ± S.E.M. Significance is determined by comparing activ-
ity counts to Day 2 (saline day). *p < 0.05.
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summarizes the temporal pattern of experiments measuring chronic dose-response to MDMA (2.5, 5.0, and 10.0 mg/kg, i.p.) for HAFigure 3
summarizes the temporal pattern of experiments measuring chronic dose-response to MDMA (2.5, 5.0, and 10.0 mg/kg, i.p.) 
for HA. The values for each 10-minute bin are presented as the mean ± S.E.M. Significance for each bin is determined by com-
paring activity counts to the same temporal bin on Day 2 (saline day). *p < 0.05.
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summarizes the temporal pattern of experiments measuring chronic dose-response to MDMA (2.5, 5.0, and 10.0 mg/kg, i.p.) for NOSFigure 4
summarizes the temporal pattern of experiments measuring chronic dose-response to MDMA (2.5, 5.0, and 10.0 mg/kg, i.p.) 
for NOS. The values for each 10-minute bin are presented as the mean ± S.E.M. Significance for each bin is determined by com-
paring activity counts to the same temporal bin on Day 2 (saline day). *p < 0.05.
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treatment groups at experimental day 39. This was done to
discern any potential interactions such as cross-tolerance
or cross-sensitization between MDMA and amphetamine
(Fig. 5) or MDMA and methylphenidate (Fig. 6). Figures
5 and 6 summarize this experiment and show that chronic
MDMA treatment did not cause any significant changes to
locomotor activity when animals were subsequently chal-
lenged with either amphetamine or methylphenidate.
Discussion
The drug MDMA has found increased prevalence in recre-
ational use over the past decade. The question of whether
or not it has the potential to elicit dependency is currently
the subject of controversy. Several experimental para-
digms used to investigate drug dependency include condi-
tioned place preference [15,23,39,43], self-administration
[44-47], and behavioral sensitization
[14,18,27,38,48,49]. Contradictory results are found
whether chronic MDMA administration modulate these
three models. Behavioral sensitization is one of the exper-
imental marker that a drug elicits dependence [25,27,36].
The objective of the present study was to use dose-
response experiments in an open-field behavioral testing
paradigm to investigate whether MDMA will elicit behav-
ioral sensitization and whether chronic MDMA adminis-
tration results in cross-sensitization to other
psychostimulants, namely amphetamine and methylphe-
nidate.
Three MDMA doses were selected for the dose-response
study (2.5, 5.0, and 10.0 mg/kg). These doses were chosen
based on similar doses used in other studies [14-
16,18,38]. Additionally, the MDMA doses administered
also fall within the range of MDMA taken recreationally
by humans [50]. The amphetamine (0.6 mg/kg) and
methylphenidate (2.5 mg/kg) doses were used to assess
cross-sensitization because these doses have been estab-
lished in a previous study to individually elicit behavioral
sensitization [29,36].
In general, MDMA caused increases in locomotor activity,
and these increases were dose-dependent i.e., increase
locomotor activities with increasing the MDMA dose.
These findings are similar to those reported by other
investigators [43,47,50]. It has been proposed that this
locomotor hyperactivity following psychostimulant
administration is a result of activation of DA-releasing
neurons located primarily in the ventral tegmental area
(VTA), nucleus accumbens (NAc), pre-frontal cortex
(PFC), and other basal ganglia structures known collec-
tively as the motive circuit [51,52]. However, locomotor
hyperactivity induced by MDMA is markedly different
from that induced by other psychostimulants such as
amphetamine [53,54]. MDMA is believed to activate 5-HT
pathways [22,55] and co-activate dopaminergic pathways
[50,55-57]. Dose-dependent increases in extracellular
dopamine (DA) have been reported in animals following
the first few hours post-MDMA administration [50]. Sev-
eral hypotheses explain how DA is released after MDMA
treatment: (1) MDMA interaction with DA uptake carrier
causes release of DA [50], (2) the release of DA is the out-
come of MDMA entry into DA nerve-ending tissue
through diffusion [58], and (3) MDMA elicits DA release
through activation of neurons by 5-HT binding of 5-HT2
receptor subtypes localized on DA releasing neurons. This
last hypothesis is based on the observation that fluoxetine
prevented the MDMA-induced release of DA [22,59].
Activation and subsequent reinforcement of primarily
dopaminergic pathways in the motive circuit (VTA, NAc,
PFC) and basal ganglia is believed to be responsible for
the onset of behavioral sensitization due to repetitive
(chronic) exposure of drugs, including classically addic-
tive psychostimulants such as cocaine and amphetamine.
This motive circuit regions is believed to mediate locomo-
tor activity, and when reinforced, lead to progressive
increases in DA and subsequent increase in locomotor
activity, characterized as behavioral sensitization [52,60-
63]. This behavioral sensitization is used as a marker to
indicate the property of a drug to have susceptibility for
dependency [25-27].
The present findings indicate that MDMA does indeed
elicit behavioral sensitization to its locomotor activating
effects similar to other psychostimulants such as cocaine
[52], amphetamine [26,28], and methylphenidate
[30,31]. The fact that MDMA sensitized to itself indicates
Table 1: Schedule of Drug Treatment
Experimental Day Day 1 Days 2–7 Days 8–12 Day 13 Day 14 Days 15–37 Day 37 Day 39
Sal Group (N = 9) Saline Saline Washout 5.0 mg/kg MDMA Amph Washout Saline Amph/MPD
2.5 Group (N = 9) Saline 2.5 mg/kg MDMA Washout 2.5 mg/kg MDMA Amph Washout Saline Amph/MPD
5.0 Group (N = 9) Saline 5.0 mg/kg MDMA Washout 5.0 mg/kg MDMA Amph Washout Saline Amph/MPD
10.0 Group (N = 9) Saline 10.0 mg/kg MDMA Washout 10.0 mg/kg MDMA Amph Washout Saline Amph/MPD
shows the schedule of drug treatment for the four experimental groups. Locomotor activity was recorded on experimental Days 1–7, 12–14, 37–
39. The numbers in the first column (2.5, 5.0, and 10.0) refer to MDMA doses (i.p.). Amph = 0.6 mg/kg amphetamine. Amph/MPD: On 
experimental Day 39, animals in each group were given either 2.5 mg/kg methylphenidate (N = 3/group) or 0.6 mg/kg amphetamine (N = 6/group).Page 7 of 12
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Behavioral sensitization following chronic treatment of
MDMA using different experimental protocols was
reported by some groups [15,18,27,38], and was disputed
by other observations [16]. This discrepancy in findings
can be partially reconciled by accounting for differences in
rat strain, sex, age, and various MDMA treatment proto-
cols used. Investigators who studied only the horizontal
activity reported that the drug elicited behavioral sensiti-
zation, while those who investigated different motor indi-
ces were not able to ascertain whether MDMA elicited
sensitization. Specifically, as reported in other studies
with psychostimulant sensitization, sensitization tends to
be most robust in animals challenged after a sufficiently
lengthy washout period following a repeated induction
phase of pre-treatment [27,30,31,36,52,63,64]. Moreo-
ver, our study analyzed four different motor indices and
showed sensitization in two of them and in the other two
indices partial sensitization, which may explain this dis-
crepancy, i.e., depending on the motor index used. There-
fore, analyzing several locomotor indices is essential.
Cross-sensitization between psychostimulants such as
between cocaine and amphetamine [65] and between
amphetamine and methylphenidate [36] has been well
characterized. Cross-sensitization between two psychos-
timulants could possibly indicate a similar mechanism in
the neural adaptations mediating behavioral sensitiza-
tion. In this study, animals previously treated with MDMA
did not show a cross-sensitized response to amphetamine
or methylphenidate. These results suggest that MDMA
elicits sensitization by a neural pathway different to that
reinforced by chronic amphetamine and methylpheni-
date. This is validated in cross- self-administration studies
performed by Ratzenboeck et al [44]. Similarly, Cole et al.
[66] reported that rats pre-treated with MDMA failed to
elicit a conditioned place preference to d-amphetamine or
cocaine. However, Fone et al. [9], Horan et al. [67], and
Achat-Mendes et al. [39] found that rats repeatedly
exposed to MDMA in adolescence exhibit an enhanced
conditioned place preference to cocaine in adulthood.
Morgan et al. [68] reported that repeated MDMA aug-
ments cocaine's ability to elevate extracellular DA levels in
the rat's nucleus accumbens. Additionally, Fletcher et al.,
[41] established that repeated pre-exposure to high doses
of MDMA facilitates acquisition of cocaine self-adminis-
tration. Callaway and Geyer [34] reported that pre-treat-
ment of rats with MDMA potentiated the activating effects
of d-amphetamine. Inconsistencies in reports investigat-
ing cross-sensitization may be explained by the differ-
ences in methodologies including (but not limited to) the
time and route of drug-administration, age and strain of
the animals tested, and experimental paradigms. How-
ever, a possible explanation supporting the failure of
MDMA to cross sensitize to other stimulants could be
given by the presence of evidence suggesting that the pri-
mary course of action of MDMA is through 5-HT releasing
neurons. While there are reports that MDMA directly
impacts DA-releasing neurons, these effects are minor in
relation to DA release by 5-HT activation [27]. Blockade of
5-HT2 receptor subtypes or serotonin transporters has
been demonstrated to be effective in limiting acute DA
release by MDMA [22,69]. The lack of a cross-sensitized
response to amphetamine and methylphenidate indicates
that MDMA may not increase the vulnerability to abuse of
other psychostimulants.
Conclusion
The findings of this study are that (1) an acute dose of
MDMA causes dose-dependent increases in locomotor
summarizes the effects of a single amphetamine (0.6 mg/kg, i.p.) injection in animals treated chronically with MDMA oraline (see Table 1) for th  HA, TD, VA, and NOS locomo-tor indices on xperiment l days 14 and 39, comparing activ-ty counts f each MDMA tre tment group to the salinegroup on the same exp rimen al dayFig re 5
summarizes the effects of a single amphetamine (0.6 mg/kg, 
i.p.) injection in animals treated chronically with MDMA or 
saline (see Table 1) for the HA, TD, VA, and NOS locomo-
tor indices on experimental days 14 and 39, comparing activ-
ity counts of each MDMA treatment group to the saline 
group on the same experimental day. The values are pre-
sented as the mean ± S.E.M. *p < 0.05.
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sient behavioral sensitization to a low dose (2.5 mg/kg) of
MDMA and produces more persistant behavioral sensiti-
zation to the higher MPD doses (5.0 and 10.0 mg/kg); (3)
chronic MDMA administration did not elicit a cross-sensi-
tized response to amphetamine or methylphenidate; and
(4) chronic administration of MDMA did not interrupt
animal growth with regard to weight.
Materials and methods
Thirty-six male Sprague Dawley rats (Harlan, Indianapo-
lis, IN), weighing 200–240 g at the beginning of experi-
ments, were housed in groups of four in Plexiglas cages in
an animal housing facility. The facility was maintained on
a 12-hour light/dark cycle (lights on at 07:00) with tem-
perature at 21 ± 2°C and the relative humidity at 38%–
42%. Water and food pellets were supplied ad libitum.
Animals were handled daily in the housing facility for five
days prior to experimental manipulation. All experiments
were carried out in accordance with the National Insti-
tutes of Health Guide for the Care and Use of Laboratory
Animals and approved by the University of Texas Center
for Laboratory Animal Medicine and Care.
After five days of habituation, animals were taken to a test-
ing room for daily experimentation. The testing room was
maintained at the same environmental conditions as the
animal housing facility. All experiments were conducted
in the testing room between 09:00 and 15:00 h. Each ani-
mal was placed individually in a computerized automated
activity test chamber that consists of an acrylic open-field
box (40.5 × 40.5 × 31.5 cm) equipped with two levels of
infrared photo-beam sensors located 6.0 and 12.5 cm
above the floor of the box (AccuScan Instruments, Colum-
bus, OH). The system checked for interruptions of each
infrared beam at a frequency of 100 Hz. Interruption of
any single beam resulted in the recording of an activity
count. Simultaneous interruptions of two or more consec-
utive beams separated by at least one second were
recorded as a movement score. This system has been pre-
viously described in detail [29,30,32,36].
Locomotor activity counts were summed into 10-minute
bins (12 bins per 120-minute session). These data were
subsequently downloaded to an IBM-compatible compu-
ter through a Versamax analyzer (AccuScan Instruments,
Columbus, OH) and sorted into various locomotor indi-
ces for analysis. Four locomotor indices were analyzed:
horizontal activity (HA), total distance (TD), vertical
activity (VA), and number of stereotypies (NOS). The HA
index measures the total number of beam interruptions
that occurred in the bottom level of infrared beams during
a given sample period; TD is a measure of the amount of
forward ambulatory activity; VA measures the total
number of beam interruptions that occurred in the upper
level of infrared beams during a given sample period; and
NOS measures the number of repetitive episodes with at
least a 1-second interval before the beginning of another
episode. The NOS index is used to assess the effect of drug
treatment on general stereotypic behaviors such as sniff-
ing, grooming, and other repetitive behaviors.
On each testing day, animals were placed in the open-field
chambers and habituated for 30 minutes, after which
injections were administered and subsequent locomotor
activity was recorded for 120 minutes. On experimental
day 1 (see Table I), all animals were injected with saline
prior to recording activity. Beginning with experimental
day 2, rats were divided into four experimental groups (N
= 9/group) consisting of three MDMA-treatment groups
(2.5, 5.0, and 10.0 mg/kg) and one control (saline) group.
On experimental days 2–7, animals were treated in their
testing cages with their respective doses of MDMA, and
animals in the control group were given saline. All ani-
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motor indices on experimental day 39, comparing activity 
counts of each MDMA treatment group to the saline group. 
The values are presented as the mean ± S.E.M. *p < 0.05.
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Behavioral and Brain Functions 2006, 2:1 http://www.behavioralandbrainfunctions.com/content/2/1/1mals were then given 5 days of washout (experimental
days 8–12). On experimental day 13, animals were re-
challenged with the same respective doses of MDMA
given during the initial 6 days of treatment. Days 14–37,
no injections were given, activity was not monitored, and
animals were kept in the housing facility. On experimen-
tal day 38, animal activity was recorded again, following
MDMA rechallenge as in experimental day 13 (Table 1).
On experimental day 39, six animals challenged with 0.6
mg/kg amphetamine and three animals with 2.5 mg/kg,
i.p., methylphenidate (Table 1). The drug treatment para-
digm was adapted from similar psychostimulant dose-
response studies previously conducted by our laboratory
[28,29,31,32,36]. Upon completion of daily locomotor
activity recordings and injection, animals were returned to
the housing facility.
All doses of (±)-3,4-methylenedioxymethamphetamine
hydrochloride (MDMA; NIDA, Research Triangle Park,
NC), d-amphetamine sulfate (Sigma-Aldrich, St. Louis,
MO), and methylphenidate hydrochloride (Mallinckrodt,
St. Louis, MO) were calculated as free base and dissolved
in 0.9% saline for administration. Injections were all
administered intraperitoneally (i.p.) and equalized with
0.9% saline to a volume of 0.8 ml so that the total volume
of injection would not vary between animals.
The acute locomotor effects of MDMA were evaluated by
comparing all three MDMA-treated groups on experimen-
tal day 2 against the saline-treated group on experimental
day 1. Sensitization to MDMA was determined by com-
paring activity scores from initial MDMA treatment
(experimental day 2) with the activity scores recorded on
the last day of MDMA maintenance (experimental day 7)
and MDMA re-challenge days (experimental days 13 and
38). The presence of MDMA cross-sensitization to
amphetamine or methylphenidate was determined
between treatment groups by comparing the activity
response to amphetamine challenge (experimental days
39) and methylphenidate challenge (experimental day
39) of the saline group (control group; animals pre-
treated with saline) with the activity response to amphet-
amine/methylphenidate challenge of the MDMA-treated
groups. Observations within groups were analyzed using
one-way Analysis of Variance (ANOVA: treatment days)
and post-hoc Fischer's LSD method. Observations
between groups were compared using the Student's paired
t-test. Statistical significance was set at p < 0.05 for all
comparisons.
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